Pacira BioSciences, Inc. (PCRX)

NasdaqGS • Currently up 0.09 (+0.25%) in today's trading session

1 member of Congress has disclosed 23 trades in Pacira BioSciences, Inc. (PCRX) via STOCK Act filings. The most recent disclosure was a purchase by Tom Malinowski on 6 May 2021. Aggregate disclosed activity totals roughly $429K in purchases (midpoint estimates from bracketed disclosure amounts).

Pacira BioSciences, Inc. is currently trading at $36.40, positioned at 100% of its 52-week range ($18.80 – $36.48).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$36.40
24h Change
+0.09 (+0.25%)
52 Week Range
$18.80–$36.48
View on NASDAQ

Pacira BioSciences, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for PCRX

Select to highlight on chart
5 transactions
Compliance: 43%
Tom Malinowski6 May 202123 Jun 2021PurchaseStock$1,001 - $15,000N/A
Tom Malinowski6 May 202113 Aug 2022PurchaseStock$1,001 - $15,000N/A
Tom Malinowski20 Apr 202112 Jun 2021PurchaseStock$1,001 - $15,000N/A
Tom Malinowski20 Apr 202113 Aug 2022PurchaseStock$1,001 - $15,000N/A
Tom Malinowski25 Jan 202113 Aug 2022PurchaseStock$1,001 - $15,000N/A

See every trade

Sign in free to see the full trade history for this stock.

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$1.45B

Volume

2.33M

Beta

0.25

P/E Ratio

14.00

Fundamentals

EPS

$2.60

Div. Yield

-

Open

$36.32

Day Range

$36.31 – $36.47

Company Information

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ · USD
Country
US
CEO
Frank D. Lee
IPO Date
2011-02-03

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable lip...

Earnings

Next Report

Q3 2026

5 Nov

EPS Est.

$0.73

Rev. Est.

$182.9M

Days Until

21

Recent Quarters

Q2 20264 Aug
EPS$0.73
Beat 13.0%
Q1 202630 Apr
EPS$0.60
Miss 1.6%
Q4 202526 Feb
EPS$0.57
Miss 32.9%
Q3 20256 Nov
EPS$0.70
Beat 7.7%
Q2 20255 Aug
EPS$0.74
Beat 2.8%
Q1 20258 May
EPS$0.62
Beat 8.8%
Q4 202427 Feb
EPS$0.91
Beat 16.7%
Q3 20246 Nov
EPS$0.79
Beat 9.7%
Q2 202430 Jul
EPS$0.89
Beat 21.9%
Q1 20247 May
EPS$0.62
Miss 3.1%
Q4 202329 Feb
EPS$0.89
Beat 0.0%
Q3 20232 Nov
EPS$0.72
Miss 14.3%
Q2 20232 Aug
EPS$0.78
Miss 3.7%
Q1 20233 May
EPS$0.53
Miss 11.7%
Q4 202228 Feb
EPS$0.80
Beat 0.0%
Q3 20223 Nov
EPS$0.64
Miss 12.3%
Q2 20223 Aug
EPS$0.51
Miss 40.0%
Q1 20224 May
EPS$0.64
Miss 13.5%
Q4 202124 Feb
EPS$0.97
Beat 16.9%
Q3 20213 Nov
EPS$0.72
Beat 9.1%
Q2 20213 Aug
EPS$0.77
Beat 1.3%
Q1 20214 May
EPS$0.53
Miss 10.2%
Q4 202025 Feb
EPS$0.87
Beat 6.1%
Q3 202029 Oct
EPS$0.68
Beat 3.0%
Q2 20206 Aug
EPS$0.12
Miss 25.0%
Q1 20207 May
EPS$0.53
Beat 65.6%
Q4 201920 Feb
EPS$0.56
Beat 27.3%
Q3 20197 Nov
EPS$0.48
Beat 41.2%
Q2 20198 Aug
EPS$0.41
Beat 20.6%
Q1 20192 May
EPS$0.22
Miss 8.3%
Q4 201828 Feb
EPS$0.47
Beat 88.0%
Q3 20181 Nov
EPS$0.31
Beat 342.9%
Q2 20182 Aug
EPS$0.24
Beat 166.7%
Q1 20183 May
EPS$0.02
Miss 66.7%
Q4 201728 Feb
EPS$0.38
Beat 216.7%
Q3 20178 Nov
EPS$0.11
Beat 298.8%
Q2 20172 Aug
EPS$-0.11
Miss 10.0%
Q1 20174 May
EPS$-0.19
Miss 430.3%
Q4 20161 Mar
EPS$0.09
Beat 588.1%
Q3 20162 Nov
EPS$0.20
Beat 1299.6%
Q2 20164 Aug
EPS$0.19
Beat 578.6%
Q1 20162 May
EPS$0.14
Beat 75.0%
Q4 201525 Feb
EPS$0.20
Miss 25.9%
Q3 201527 Oct
EPS$0.32
Beat 113.3%
Q2 201530 Jul
EPS$0.20
Beat 0.0%
Q1 201530 Apr
EPS$0.23
Beat 27.8%
Q4 201424 Feb
EPS$0.35
Beat 16.7%
Q3 201430 Oct
EPS$0.14
Miss 30.0%
Q2 201431 Jul
EPS$0.04
Beat 116.7%
Q1 20141 May
EPS$-0.19
Beat 36.7%
Q4 201325 Feb
EPS$-0.23
Beat 25.8%
Q3 201331 Oct
EPS$-0.30
Beat 16.7%
Q2 20136 Aug
EPS$-0.42
Beat 2.3%
Q1 20138 May
EPS$-0.61
Miss 24.5%
Q4 20127 Mar
EPS$-0.50
Miss 21.9%
Q3 20121 Nov
EPS$-0.49
Miss 11.4%
Q2 20129 Aug
EPS$-0.23
Beat 46.5%
Q1 20129 May
EPS$-0.47
Miss 20.5%
Q4 201127 Mar
EPS$-0.58
Miss 7.4%
Q3 201131 Oct
EPS$-0.55
Beat 6.8%
Q2 201111 Aug
EPS$-0.51
Beat 12.1%
Q1 201111 May
EPS$-0.98
Miss 84.9%
Q2 201030 Sept
EPS$-13.77
Q1 201030 Jun
EPS$-11.86
Q4 200931 Mar
EPS$-9.39
Q3 200931 Dec
EPS$-15.62
Q2 200930 Sept
EPS$-11.48

2 politicians traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

CELC

Celcuity Inc.

47
$59.90-3.29 (-5.21%)
Healthcare
Held by same politician
Same sector: Healthcare
1 politician
View Stock

TSLA

Tesla, Inc.

20
$367.16-8.07 (-2.15%)
Consumer Cyclical
Held by same politician
Significant holdings value
1 politician
View Stock

TPR

Tapestry, Inc.

17
$115.03-0.20 (-0.17%)
Consumer Cyclical
Held by same politician
1 politician
View Stock

Frequently Asked Questions about PCRX

Which members of Congress have traded PCRX?
1 member of Congress has disclosed 23 trade in Pacira BioSciences, Inc. (PCRX) under the STOCK Act: Tom Malinowski.
When was PCRX most recently disclosed by Congress?
The most recent PCRX disclosure was a purchase by Tom Malinowski on 6 May 2021.
What is the total disclosed congressional trading volume for PCRX?
Members of Congress have disclosed approximately $429K in PCRX purchases (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in PCRX?
This PCRX page updates as soon as new STOCK Act disclosures are filed for Pacira BioSciences, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.